Key Takeaways
- The AtaiBeckley (ATAI) acquisition by Eli Lilly was finalized on September 11, 2026
- Shareholders of AtaiBeckley were paid $6.75 cash per share along with one contingent value right
- Additional milestone-based payments through CVRs could reach $2.50 per share upon meeting clinical and regulatory targets
- Shares of AtaiBeckley climbed approximately 80% during the six-month period preceding the transaction closure, ending at $7.35
- The company has initiated delisting procedures from Nasdaq by filing the necessary Form 25 documentation
On Friday, September 11, 2026, Eli Lilly (LLY) finalized its takeover of AtaiBeckley Inc. (ATAI), making the mental health-focused biotech a fully owned subsidiary.
The transaction structure provided AtaiBeckley stockholders with $6.75 cash for each share they owned, supplemented by one contingent value right. The immediate equity valuation for the transaction totaled roughly $2.8 billion.
Should certain clinical development and regulatory objectives be achieved, the CVRs may deliver an additional $2.50 per share, potentially elevating the complete transaction worth to $3.8 billion. These conditional payments depend on hitting predetermined milestones throughout the next several years.
The CVR payment structure includes: a maximum of $1.00 per share contingent on initiating a Phase 3 study for VLS-01 within a four-year window, up to $0.50 per share following U.S. regulatory approval and DEA rescheduling of BPL-003 within five years, and as much as $1.00 per share after securing U.S. approval and DEA rescheduling for VLS-01 within seven years.
The CVRs cannot be traded and won’t appear on any stock exchange. They provide no ownership stake or shareholder voting privileges.
When the deal concluded, AtaiBeckley shares were changing hands at $7.35, modestly higher than the $6.75 base payment, suggesting investors assigned some probability to the CVR milestones being achieved. During the half-year preceding the completion, the stock had appreciated approximately 80%.
AtaiBeckley’s Strategic Value for Lilly
AtaiBeckley specializes in creating fast-acting neuroplastogenic compounds designed to treat mental health disorders. BPL-003, its primary clinical asset, is being developed for patients with treatment-resistant depression.
According to Carole Ho, who leads Lilly’s neuroscience division, the acquisition aligns with the company’s objective to shift from long-term dosing regimens toward quicker-acting therapeutic options for individuals who haven’t benefited from currently available medications.
Wall Street Response Varied Across Firms
Upon the initial announcement of the transaction, Wall Street analysts offered divergent perspectives. Multiple firms including Deutsche Bank, H.C. Wainwright, and Jefferies revised their ratings downward for AtaiBeckley stock.
Deutsche Bank shifted its stance to Hold from Buy, reducing its price objective to $8.00 from $12.00. H.C. Wainwright changed to Neutral from Buy, dramatically lowering its target to $7.50 from $25. Jefferies similarly adopted a Hold rating, bringing down its target to $7.50 from $10.00.
Oppenheimer stood apart from the consensus, maintaining its Outperform recommendation along with a $16.00 price target.
AtaiBeckley’s shareholder base voted to approve the transaction during a specially convened meeting prior to the closing date.
The entire AtaiBeckley board of directors and executive leadership team resigned at the closing. Management and directors from Merger Sub, a Lilly-controlled entity, assumed these positions.
Corporate governance documents including the certificate of incorporation and bylaws were modified according to merger agreement provisions. Every pre-existing equity compensation program was discontinued upon completion.
AtaiBeckley has informed Nasdaq that the merger has concluded and sought a halt to trading activity in its shares. The company has requested that Nasdaq submit a Form 25 to the SEC initiating the delisting process. Additionally, AtaiBeckley intends to file Form 15 to terminate its SEC disclosure requirements.
LLY stock declined 0.33% during the trading session, closing at $1,119.26.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
